These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 19442777)

  • 21. Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.
    Jensen JT; Garie SG; Trummer D; Elliesen J
    Contraception; 2012 Aug; 86(2):110-8. PubMed ID: 22281416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
    Ahrendt HJ; Nisand I; Bastianelli C; Gómez MA; Gemzell-Danielsson K; Urdl W; Karskov B; Oeyen L; Bitzer J; Page G; Milsom I
    Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight.
    Endrikat J; Sandri M; Gerlinger C; Rübig A; Schmidt W; Fortier M
    Eur J Contracept Reprod Health Care; 2007 Sep; 12(3):220-8. PubMed ID: 17763260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism.
    Batukan C; Muderris II
    Fertil Steril; 2006 Feb; 85(2):436-40. PubMed ID: 16595223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome.
    De Leo V; Morgante G; Piomboni P; Musacchio MC; Petraglia F; Cianci A
    Fertil Steril; 2007 Jul; 88(1):113-7. PubMed ID: 17418832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen.
    Hernádi L; Marr J; Trummer D; De Leo V; Petraglia F
    Contraception; 2009 Jul; 80(1):18-24. PubMed ID: 19501211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study.
    Schramm G; Heckes B
    Contraception; 2007 Aug; 76(2):84-90. PubMed ID: 17656175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
    Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A
    Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy and safety of drospirenone-ethinylestradiol on contraception in healthy Chinese women: a multicenter randomized controlled trial].
    Fan GS; Bian ML; Cheng LN; Cao XM; Huang ZR; Han ZY; Jing XP; Li J; Wu SY; Xiong CL; Xiong ZA; Yue TF
    Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):38-44. PubMed ID: 19563061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. YAZ and the novel progestin drospirenone.
    Mishell DR
    J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen.
    Coffee AL; Kuehl TJ; Willis S; Sulak PJ
    Am J Obstet Gynecol; 2006 Nov; 195(5):1311-9. PubMed ID: 16796986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
    Pearlstein TB; Bachmann GA; Zacur HA; Yonkers KA
    Contraception; 2005 Dec; 72(6):414-21. PubMed ID: 16307962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)--an open-label, prospective, noncontrolled, office-based Phase III study.
    Zahradnik HP; Hanjalic-Beck A
    Contraception; 2008 May; 77(5):337-43. PubMed ID: 18402849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse).
    Barbosa IC; Filho CI; Faggion D; Baracat EC
    Contraception; 2006 Jan; 73(1):30-3. PubMed ID: 16371291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone.
    Milsom I; Lete I; Bjertnaes A; Rokstad K; Lindh I; Gruber CJ; Birkhäuser MH; Aubeny E; Knudsen T; Bastianelli C
    Hum Reprod; 2006 Sep; 21(9):2304-11. PubMed ID: 16763008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Yasmin: the reason why.
    Thorneycroft IH
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol.
    Paoletti AM; Lello S; Fratta S; Orrù M; Ranuzzi F; Sogliano C; Concas A; Biggio G; Melis GB
    Fertil Steril; 2004 Mar; 81(3):645-51. PubMed ID: 15037415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study.
    Gargano V; Massaro M; Morra I; Formisano C; Di Carlo C; Nappi C
    Contraception; 2008 Jul; 78(1):10-5. PubMed ID: 18555812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Added benefits of drospirenone for compliance.
    Foidart JM
    Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome.
    Pehlivanov B; Mitkov M
    Eur J Contracept Reprod Health Care; 2007 Mar; 12(1):30-5. PubMed ID: 17455042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.